Everolimus improves the efficacy of dasatinib in

PDGFRα-driven glioma

Zachary Miklja^{1^}, Viveka Nand Yadav^{1^}, Rodrigo T. Cartaxo¹, Ruby Siada¹, Chase C. Thomas¹, Jessica R. Cummings¹, Brendan Mullan¹, Stefanie Stallard¹, Alyssa Paul¹, Amy K. Bruzek², Kyle Wierzbicki¹, Tao Yang³, Taylor Garcia¹, Ian Wolfe¹, Marcia Leonard¹, Patricia L. Robertson³, Hugh J.L. Garton², Daniel R. Wahl⁴, Hemant Parmar⁵, Jann N. Sarkaria⁶, Cassie Kline⁷, Sabine Mueller⁷, Theodore Nicolaides⁸, Chana Glasser⁹, Sarah E.S. Leary¹⁰, Sriram Venneti¹¹, Chandan Kumar-Sinha^{11,12}, Arul M. Chinnaiyan^{11,12,13,14,15}, Rajen Mody¹, Manjunath P. Pai¹⁶, Timothy N. Phoenix¹⁷, Bernard L. Marini¹⁶, Carl Koschmann^{1*}

*Correspondence to: <u>ckoschma@med.umich.edu</u>

This PDF file includes:

Supplementary methods Supplementary figures

Supplemental materials

Supplementary methods

Neurosphere Limiting Dilution Assay

PPK cells were serially diluted in triplicate at 62, 31, 15, 7, or 3 cells/well in 96 well plates and kept for 24h in an incubator at $37^{\circ}C/5\%CO_2$. Dasatinib and everolimus alone or in combination were added to the plates and sphere growth was monitored for 6 days. When they reached 50 µm in the control condition (DMSO), spheres above 20 µm in every well were counted and the average number plotted for each cell density originally plated.

P-gp assay

In vitro P-gp inhibitor assay was performed with the Pgp-Glo[™] Assay System (Promega). Assay methods were executed as described in the supplied protocol. Briefly, the assay detected the effects of compounds on recombinant human P-gp in a cell membrane fraction. The assay utilized the ATP dependence of the light-generating reaction (firefly luciferase) of ATPase inhibition. Verapamil is a P-gp substrate that stimulates P-gp ATPase activity and, within the assay, functions as a P-gp stimulator (negative control). Sodium orthovanadate (Na₃VO₄) provides a measure of P-gp independent ATPase activity and was used as a P-gp inhibitor (positive control) within this assay. All experimental conditions were briefly rocked on a plate shaker and then put in an incubator at 37°C and 5% CO₂ for 3.5 hours. After this incubation period, all conditions were again briefly rocked on a plate shaker and incubated at room temperature for 20 minutes to allow luminescent signal to develop. Luminescent signal (ATM inhibition) was read on a Synergy HTX Multi-Mode microplate reader (BioTek).

Human cerebrospinal fluid tumor DNA (CSF-tDNA) analysis

Tumor DNA analysis was performed by droplet digital PCR (ddPCR), a highly sensitive PCR method that can detect low copy numbers of DNA, including ctDNA, in CSF. PCR primers and fluorescent probes were designed for the wild-type *PDGFRA* and mutant D842V sequences, as well as the target amplification region. An additional assay was designed for the housekeeping gene *AP3B1* to be used as a reference (Bio-Rad). Patient sample CSF underwent ddPCR to document baseline CSF tDNA in UMPED52 and baseline CSF tDNA *PDGFRA* copy number in UMPED44. The Bio-Rad QX200 AutoDG system was used for all ddPCR work, and Bio-Rad QuantaSoft Analysis Pro was used for analysis of results.

Western blot and immunohistochemistry

PDGFRα pathway expression was assessed in primary HGG cell cultures and mouse brain/tumor tissue via immunocytochemistry (1:500) and western blotting (1:1000) with PDGF Receptor α antibody (Cell Signaling, sc-3174S) and Phospho-PDGF Receptor α antibody (Cell Signaling sc-3170S). PDGFRα/MAPK pathway expression was assessed in primary mouse and human HGG cell culture via western blotting (1:500) with Phospho-Src antibody (Cell Signaling, #6943S), Src antibody (Cell Signaling, #2109S), Phospho-ERK1/2 antibody (Cell Signaling, #4695S), and ERK1/2 antibody (Santa Cruz Biotechnology, sc-514302). Expression for the mTOR pathway was assessed via western blotting using Phospho-S6 antibody (Cell Signaling, #4858S), S6 antibody (Cell Signaling, #2217S), Phospho-p70 S6 Kinase antibody (Cell Signaling, #9234T), and p70 S6 Kinase antibody (Cell Signaling, #2708T). P-glycoprotein (P-gp) expression in PDGFRα-driven HGG mouse brain and tumor tissue was assessed by immunohistochemistry (1:50) with P-gp antibody (Santa Cruz Biotechnology, sc-390883). Phospho-Src, total Src, phospho-S6, and total S6 expression in PDGFRAdriven HGG mouse brain and tumor tissue were assessed by immunohistochemistry with Phospho-Src antibody (Cell Signaling, #6943S), Src antibody (Cell Signaling, #2109S), Phospho-S6 antibody (Cell Signaling, #4858S), and S6 antibody (Cell Signaling, #2217S), respectively.

Supplementary Figures




Figure S1: Characterization of IUE PPK generated tumors and primary cell culture **A**) Representative coronal plane image of mouse brain with IUE PPK tumor (80-90% cortex effaced) (left). Tumor images for IUE PPK generated tumors depicting high-grade features including necrosis and vascular proliferation (right). **B**) IHC for IUE PPK tumors demonstrating increased total PDGFR α , tumor-specific positive staining for H3K27M, and negative staining for H3K27me3. **C**) Sequencing of PPK cells for genes *DNp53*, *PDGFRA* D842V and *H3.3*K27M. **D**) Quantification of p-PDGFR α and total PDGFR α expression in western blot of PPK cells with PDGF α / β ligand supplementation. **E**) Growth response of human HGG tumor cells with *PDGFRA* amplification (UMPED58) after supplementation with or without ligands PDGF α and β (**** *P* ≤ 0.00005 by two-tailed Welch's t-test). Data represent mean ± SEM. Scale bars: A(top): left 200 µm, right 100 µm; (bottom) up 200 µm, down 50 µm. Sanger Institute – Genomics Of Drug Sensitivity (GDSC)

Α





Figure S2: Sensitivity of human primary cell cultures to treatment with dasatinib **A)** Dasatinib dose-response curve for various cancer types (data from the Sanger Institute – Genomics of Drug Sensitivity). Most low-grade glioma and glioblastoma mutliforme cell cultures were sensitive to dasatinib within 0.01 to 1 μ M ranges (red region).






Figure S3: Effect of dasatinib and everolimus monotherapy or co-administration on RTK/MAPK/mTOR pathways A) Western blot data assessing the effect of dasatinib

monotherapy, everolimus monotherapy, or co-administration of both drugs in vitro on RTK/MAPK and mTOR pathways in mouse *PDGFRA*-mutant HGG cell line (left) or human *PDGFRA*-enhanced HGG cell line (right). Expression of p-PDGFRa/ β (Y849/Y857), p-Src (Y416), p-ERK (Thr202/Tyr204), p-S6 (S235-236), p-p70 S6 Kinase (Thr389), and Alpha-Tubulin (control) were analyzed. In the co-administration condition, drugs were administered at equal doses (doses indicated in text above figure).

p-PDGFRα/β Y849/Y857




Figure S4: Quantification of western blot data shown in Supplemental Figure 3 **A**) Western blot data quantification showing that when compared to dasatinib or everolimus monotherapy, co-treatment of both drugs resulted in reduced expression of p-PDGFR α/β (Y849/Y857) in mouse PDGFRA-mutant glioma (PPK) cells at 1 and 10 uM doses. Co-treatment also resulted in reduced expression of p-S6 (S235-236) at 0.1 uM in PPK cells and at all administered concentrations in human PDGFRA-enhanced HGG (XIII-P) cells.




Figure S5: Dasatinib and everolimus efficacy in PPK neurospheres and P-gp inhibition over time. **A)** Representative PPK neurosphere images (n=3 per group) after treatment with dasatinib and everolimus monotherapy or in combination. **B)** P-gp inhibition by varying concentrations of everolimus over time using in vitro assay (n=5 technical replicates). [Data represent mean \pm SEM].




Figure S6: Pharmacokinetic (PK) analysis of dasatinib concentrations in non-tumor mouse model **A)** Schematic of PK mouse studies (tail vein injection (TVI) and oral gavage (OG)). **B)** Dasatinib plasma concentration (ng/mL) over time for treatment with dasatinib alone and

dasatinib with everolimus. No statistical significance was found between treatment groups at any time points by two-tailed Welch's t-tests. **C)** Dasatinib cortex concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. Statistical significance was found between treatment groups at the 4 hour time point (**** $P \le 0.05$ by two-tailed Welch's t-test). No other statistical significance was found. **D)** Dasatinib brainstem concentration (ng/mL) over time for treatment with dasatinib alone and dasatinib with everolimus. No statistical significance was found between treatment groups at any time points by two-tailed Welch's t-tests. **E)** Dasatinib concentration (ng/mL) for plasma, cortex, and brainstem over time when treated with dasatinib alone. **F)** Dasatinib concentration (ng/mL) for plasma, cortex, and brainstem over time when treated with dasatinib and everolimus. [Data represent mean \pm SEM for B-F].




Figure S7: PK analysis of everolimus blood and brain concentration in non-tumor mouse model **A**) Everolimus plasma concentrations of (ng/mL) over time after treatment with everolimus [n=3 replicates]. **B**) Everolimus brain concentrations (ng/g) over time after treatment with everolimus [n=3 replicates]. [Data represent mean \pm SEM for A and B].







Figure S8: Immunohistochemistry of mouse tumors co-treated with dasatinib and everolimus immediately prior to processing. **A)** P-gp expression in the treated condition was shown to be reduced when compared to the untreated condition. Red arrows represent positive staining cells. Scale bars (from left to right): 200 µm; 200 µm; 50 µm. **B)** IHC quantification for P-gp expression shown in part A (*** $P \le 0.0005$ by two-tailed Welch's t-test) [n=6 replicates for untreated group and n=5 replicates for everolimus+dasatinib group]. [Data represent mean \pm SEM].





p-Src







Untreated (DMSO)

- Dasatinib
- Everolimus
- Dasatinib + Everolimus









- Untreated (DMSO)
- Dasatinib
- Everolimus
- Dasatinib + Everolimus

Figure S9. Effect of dasatinib and everolimus co-treatment or monotherapy on p-Src and p-S6 expression levels. **A)** Representative IHC staining images [n=3 mice per treatment

group]. Whole brain images with tumors outlined in red and 20x magnification tumor images are shown for p-Src, total Src (T-Src), p-S6, and total S6 (T-S6) staining. Dasatinib and everolimus co-treatment displayed the lowest staining for p-Src and p-S6. **B)** IHC quantification data for p-Src, p-S6, total Src, and total S6, showing the greatest reduction in expression levels in the co-treatment group when compared to the untreated group [n=3 animals per treatment group, 4 images per animal]. Statistical significance (see Figure 3) was found between the untreated group and co-treatment group for p-Src and p-S6 expression (**** P ≤ 0.0001 by Dunnett's multiple comparisons test). [Data represent mean \pm SEM.






Figure S10: Pharmacokinetic (PK) analysis of dasatinib concentrations in plasma and CSF in patients **A**) Time course depicting when MRI images and dasatinib plasma + CSF PK analyses were performed during treatment of two human patients with PDGFRα-driven glioma (UMPED44 and UMPED52). **B**) Comparison of plasma dasatinib concentrations for dasatinib alone and dasatinib and everolimus co-treatment for UMPED44 and UMPED52. **C**) Comparison of CSF dasatinib concentrations for dasatinib alone and dasatinib concentrations for dasatinib alone and dasatinib and everolimus co-treatment for UMPED44 and UMPED52. **C**)

UMPED52 Copy Number Profile






Gene	Effect	Protein Change	Variant Allele Fraction
PDGFRA	Missense	p.D842V	28%
DCC	Missense	p.T146l	31%
ACVR2B	Missense	p.E1039*	20%



D

В





Tumor size: 908 mm² Plasma dasatinib: 26.4 ng/ml CSF dasatinib: N/A

Tumor size: 902 mm² Plasma dasatinib: 165 ng/ml CSF dasatinib: N/A





Tumor size: 1272 mm²

Figure S11: Molecular attributes and tumor imaging of *PDGFRA*-mutated tail patient (UMPED52) **A**) UMPED52 copy number profile with estimated tumor content. **B**) UMPED52 somatic variants with a *PDGFRA* variant allele fraction of 34%. **C**) UMPED52 baseline CSF tDNA documenting *PDGFRA* D824V allele fraction. **D**) Serial UMPED52 MRI (axial FLAIR T2) at baseline, pre cycle 3, and pre cycle 4.






Figure S12: PedcBioPortal (adult HGG) P-gp RNA-seq data **A)** No statistical significance was found between P-gp expression and *PDFGRA* status, age at diagnosis, or *MGMT* status within these adult data sets. Data represent mean \pm SEM.